Development and applications of mRNA treatment based on lipid nanoparticles

被引：30

作者：

Wang, Zhe ^{[1
]}

Ma, Wanting ^{[1
]}

Fu, Xingxing ^{[1
]}

Qi, Yanfei ^{[2
]}

Zhao, Yinan ^{[1
]}

Zhang, Shubiao ^{[1
]}

机构：

[1] Dalian Minzu Univ, Minist Educ, Key Lab Biotechnol & Bioresources Utilizat, Dalian 116600, Peoples R China

[2] Univ Sydney, Centenary Inst, Sydney, NSW 2050, Australia

来源：

BIOTECHNOLOGY ADVANCES | 2023年 / 65卷

基金：

中国国家自然科学基金;

关键词：

Lipid nanoparticles; mRNA vaccine; Infectious disease; Antitumor; Genetic diseases; IN-VIVO; MEDIATED DELIVERY; CATIONIC LIPIDS; DENDRITIC CELLS; ZIKA VIRUS; INTRACELLULAR DELIVERY; PROTEIN EXPRESSION; NONVIRAL DELIVERY; RATIONAL DESIGN; VACCINE;

D O I：

10.1016/j.biotechadv.2023.108130

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Nucleic acid-based therapies such as messenger RNA have the potential to revolutionize modern medicine and enhance the performance of existing pharmaceuticals. The key challenges of mRNA-based therapies are delivering the mRNA safely and effectively to the target tissues and cells and controlling its release from the delivery vehicle. Lipid nanoparticles (LNPs) have been widely studied as drug carriers and are considered to be state-of-the-art technology for nucleic acid delivery. In this review, we begin by presenting the advantages and mechanisms of action of mRNA therapeutics. Then we discuss the design of LNP platforms based on ionizable lipids and the applications of mRNA-LNP vaccines for prevention of infectious diseases and for treatment of cancer and various genetic diseases. Finally, we describe the challenges and future prospects of mRNA-LNP therapeutics.

引用

页数：23

共 218 条

[1] mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
A Feldman, Robert
Fuhr, Rainard
Smolenov, Igor
Ribeiro, Amilcar
Panther, Lori
Watson, Mike
Senn, Joseph J.
Smith, Mike
Almarsson, Orn
Pujar, Hari S.
Laska, Michael E.
Thompson, James
Zaks, Tal
Ciaramella, Giuseppe
[J]. VACCINE, 2019, 37 (25) : 3326 - 3334
[2] Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Abu-Raddad, Laith J.
Chemaitelly, Hiam
Butt, Adeel A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02) : 187 - 189
[3] Development of Lipidoid-siRNA Formulations for Systemic Delivery to the Liver
Akinc, Akin
Goldberg, Michael
Qin, June
Dorkin, J. Robert
Gamba-Vitalo, Christina
Maier, Martin
Jayaprakash, K. Narayanannair
Jayaraman, Muthusamy
Rajeev, Kallanthottathil G.
Manoharan, Muthiah
Koteliansky, Victor
Roehl, Ingo
Leshchiner, Elizaveta S.
Langer, Robert
Anderson, Daniel G.
[J]. MOLECULAR THERAPY, 2009, 17 (05) : 872 - 879
[4] Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial
Al Kaabi, Nawal
Zhang, Yuntao
Xia, Shengli
Yang, Yunkai
Al Qahtani, Manaf M.
Abdulrazzaq, Najiba
Al Nusair, Majed
Hassany, Mohamed
Jawad, Jaleela S.
Abdalla, Jehad
Hussein, Salah Eldin
Al Mazrouei, Shamma K.
Al Karam, Maysoon
Li, Xinguo
Yang, Xuqin
Wang, Wei
Lai, Bonan
Chen, Wei
Huang, Shihe
Wang, Qian
Yang, Tian
Liu, Yang
Ma, Rui
Hussain, Zaidoon M.
Khan, Tehmina
Saifuddin Fasihuddin, Mohammed
You, Wangyang
Xie, Zhiqiang
Zhao, Yuxiu
Jiang, Zhiwei
Zhao, Guoqing
Zhang, Yanbo
Mahmoud, Sally
ElTantawy, Islam
Xiao, Peng
Koshy, Ashish
Zaher, Walid Abbas
Wang, Hui
Duan, Kai
Pan, An
Yang, Xiaoming
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (01): : 35 - 45
[5] Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
Alameh, Mohamad-Gabriel
Tombacz, Istvan
Bettini, Emily
Lederer, Katlyn
Sittplangkoon, Chutamath
Wilmore, Joel R.
Gaudette, Brian T.
Soliman, Ousamah Y.
Pine, Matthew
Hicks, Philip
Manzoni, Tomaz B.
Knox, James J.
Johnson, John L.
Laczko, Dorottya
Muramatsu, Hiromi
Davis, Benjamin
Meng, Wenzhao
Rosenfeld, Aaron M.
Strohmeier, Shirin
Lin, Paulo J. C.
Mui, Barbara L.
Tam, Ying K.
Kariko, Katalin
Jacquet, Alain
Krammer, Florian
Bates, Paul
Cancro, Michael P.
Weissman, Drew
Prak, Eline T. Luning
Allman, David
Locci, Michela
Pardi, Norbert
[J]. IMMUNITY, 2021, 54 (12) : 2877 - +
[6] Alasvand N, 2017, MULTIFUNCTIONAL SYSTEMS FOR COMBINED DELIVERY, BIOSENSING AND DIAGNOSTICS, P245, DOI 10.1016/B978-0-323-52725-5.00013-7
[7] Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial
Aldrich, Cassandra
Leroux-Roels, Isabel
Huang, Katell Bidet
Bica, Mihai Alexandru
Loeliger, Edde
Schoenborn-Kellenberger, Oliver
Walz, Lisa
Leroux-Roels, Geert
von Sonnenburg, Frank
Oostvogels, Lidia
[J]. VACCINE, 2021, 39 (08) : 1310 - 1318
[8] A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults
Aliprantis, Antonios O.
Shaw, Christine A.
Griffin, Paul
Farinola, Nicholas
Railkar, Radha A.
Cao, Xin
Liu, Wen
Sachs, Jeffrey R.
Swenson, Christine J.
Lee, Heather
Cox, Kara S.
Spellman, Daniel S.
Winstead, Colleen J.
Smolenov, Igor
Lai, Eseng
Zaks, Tal
Espeseth, Amy S.
Panther, Lori
[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (05) : 1248 - 1261
[9] Liposomal drug delivery systems: From concept to clinical applications
Allen, Theresa M.
Cullis, Pieter R.
[J]. ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) : 36 - 48
[10] Poloxamers, poloxamines and polymeric micelles: Definition, structure and therapeutic applications in cancer
Almeida, Mauro
Magalhes, Mariana
Veiga, Francisco
Figueiras, Ana
[J]. JOURNAL OF POLYMER RESEARCH, 2017, 25 (01)

← 1 2 3 4 5 6 7 8 9 10 →